Induction of a robust T- and B-cell immune response in non- and low-responders to conventional vaccination against hepatitis B by using a third generation PreS/S vaccine

Vaccine

Volumn 32, Issue 39, 2014, Pages 5077-5082

  Krawczyk, Adalbert ^a   Ludwig, Charlotte ^a   Jochum, Christoph ^a   Fiedler, Melanie ^a   Heinemann, Falko M ^a   Shouval, Daniel ^b   Roggendorf, Michael ^a   Roggendorf, Hedwig ^c   Lindemann, Monika ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Cellular immune response; Hepatitis B Virus; Third generation hepatitis B vaccine; Vaccination failure

Indexed keywords

GAMMA INTERFERON; HEPATITIS B SURFACE ANTIBODY; HLA DRB1 ANTIGEN; RECOMBINANT HEPATITIS B VACCINE; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; PRESURFACE PROTEIN 1, HEPATITIS B SURFACE ANTIGEN; PRESURFACE PROTEIN 2, HEPATITIS B SURFACE ANTIGEN; PROTEIN PRECURSOR;

ADULT; AGED; ANTIBODY TITER; ARTICLE; CELLULAR IMMUNITY; DRUG APPROVAL; DRUG RESPONSE; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HEPATITIS B; HLA SYSTEM; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNE RESPONSE; LYMPHOCYTE PROLIFERATION; MALE; MIDDLE AGED; NORMAL HUMAN; PRIORITY JOURNAL; VACCINATION; VACCINE FAILURE; YOUNG ADULT; B LYMPHOCYTE; BLOOD; IMMUNIZATION; IMMUNOLOGY; T LYMPHOCYTE;

ADULT; AGED; B-LYMPHOCYTES; FEMALE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNIZATION SCHEDULE; INTERFERON-GAMMA; MALE; MIDDLE AGED; PROTEIN PRECURSORS; T-LYMPHOCYTES; YOUNG ADULT;

EID: 84906083907     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.06.076     Document Type: Article

References (46)

1. Hou J., Liu Z., Gu F. Epidemiology and prevention of hepatitis B virus infection. Int J Med Sci 2005, 2:50-57.
2. Stoop J.N., van der Molen R.G., Baan C.C., van der Laan L.J., Kuipers E.J., Kusters J.G., et al. Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection. Hepatology 2005, 41:771-778.
3. Bertoletti A., Gehring A.J. The immune response during hepatitis B virus infection. J Gen Virol 2006, 87:1439-1449.
4. Ott J.J., Stevens G.A., Groeger J., Wiersma S.T. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine 2012, 30:2212-2219.
5. Kubba A.K., Taylor P., Graneek B., Strobel S. Non-responders to hepatitis B vaccination: a review. Commun Dis Public Health 2003, 6:106-112.
6. Han K., Shao X., Zheng H., Wu C., Zhu J., Zheng X., et al. Revaccination of non- and low-responders after a standard three dose hepatitis B vaccine schedule. Hum Vaccin Immunother 2012, 8:1845-1849.
7. Craven D.E., Awdeh Z.L., Kunches L.M., Yunis E.J., Dienstag J.L., Werner B.G., et al. Nonresponsiveness to hepatitis B vaccine in health care workers. Results of revaccination and genetic typings. Ann Intern Med 1986, 105:356-360.
8. Alper C.A., Kruskall M.S., Marcus-Bagley D., Craven D.E., Katz A.J., Brink S.J., et al. Genetic prediction of nonresponse to hepatitis B vaccine. N Engl J Med 1989, 321:708-712.
9. Höhler T., Meyer C.U., Notghi A., Stradmann-Bellinghausen B., Schneider P.M., Starke R., et al. The influence of major histocompatibility complex class II genes and T-cell Vbeta repertoire on response to immunization with HBsAg. Hum Immunol 1998, 59:212-218.
10. Rendi-Wagner P., Shouval D., Genton B., Lurie Y., Rumke H., Boland G., et al. Comparative immunogenicity of a PreS/S hepatitis B vaccine in non- and low responders to conventional vaccine. Vaccine 2006, 24:2781-2789.
11. Shouval D., Ilan Y., Adler R., Deepen R., Panet A., Even-Chen Z., et al. Improved immunogenicity in mice of a mammalian cell-derived recombinant hepatitis B vaccine containing pre-S1 and pre-S2 antigens as compared with conventional yeast-derived vaccines. Vaccine 1994, 12:1453-1459.
12. Milich D.R., McNamara M.K., McLachlan A., Thornton G.B., Chisari F.V. Distinct H-2-linked regulation of T-cell responses to the pre-S and S regions of the same hepatitis B surface antigen polypeptide allows circumvention of nonresponsiveness to the S region. Proc Nat Acad Sci USA 1985, 82:8168-8172.
13. Yap I., Chan S.H. A new pre-S containing recombinant hepatitis B vaccine and its effect on non-responders: a preliminary observation. Ann Acad Med Singapore 1996, 25:120-122.
14. Shapira M.Y., Zeira E., Adler R., Shouval D. Rapid seroprotection against hepatitis B following the first dose of a Pre-S1/Pre-S2/S vaccine. J Hepatol 2001, 34:123-127.
15. Sylvan S.P., Madalinski K., Hellström U.B. Anti-preS responses influence the anti-HBs response in newborns after vaccination with the third generation Sci-B-Vac vaccine. Vaccine 2009, 28:446-451.
16. Hourvitz A., Mosseri R., Solomon A., Yehezkelli Y., Atsmon J., Danon Y.L., et al. Reactogenicity and immunogenicity of a new recombinant hepatitis B vaccine containing Pre S antigens: a preliminary report. J Viral Hepatitis 1996, 3:37-42.
17. Raz R., Dagan R., Gallil A., Brill G., Kassis I., Koren R. Safety and immunogenicity of a novel mammalian cell-derived recombinant hepatitis B vaccine containing Pre-S1 and Pre-S2 antigens in children. Vaccine 1996, 14:207-211.
18. Yerushalmi B., Raz R., Blondheim O., Shumov E., Koren R., Dagan R. Safety and immunogenicity of a novel mammalian cell-derived recombinant hepatitis B vaccine containing Pre-S1 and Pre-S2 antigens in neonates. Pediatr Infect Dis J 1997, 16:587-592.
19. Celis E., Kung P.C., Chang T.W. Hepatitis B virus-reactive human T lymphocyte clones: antigen specificity and helper function for antibody synthesis. J Immunol 1984, 132:1511-1516.
20. Diminsky D., Moav N., Gorecki M., Barenholz Y. Physical, chemical and immunological stability of CHO-derived hepatitis B surface antigen (HBsAg) particles. Vaccine 1999, 18:3-17.
21. Diminsky D., Schirmbeck R., Reimann J., Barenholz Y. Comparison between hepatitis B surface antigen (HBsAg) particles derived from mammalian cells (CHO) and yeast cells (Hansenula polymorpha): composition, structure and immunogenicity. Vaccine 1997, 15:637-647.
22. Heinemann F.M. HLA genotyping and antibody characterization using the Luminex™ multiplex technology. Transfus Med Hemother 2009, 36:273-278.
23. Schumann A., Fiedler M., Dahmen U., Grosse-Wilde H., Roggendorf M., Lindemann M. Cellular and humoral immune response to a third generation hepatitis B vaccine. J Viral Hepatitis 2007, 14:592-598.
24. Shepard C.W., Simard E.P., Finelli L., Fiore A.E., Bell B.P. Hepatitis B virus infection: epidemiology and vaccination. Epidemiol Rev 2006, 28:112-125.
25. Beasley R.P. Rocks along the road to the control of HBV and HCC. Ann Epidemiol 2009, 19:231-234.
26. Yap I., Guan R., Chan S.H. Recombinant DNA hepatitis B vaccine containing Pre-S components of the HBV coat protein-a preliminary study on immunogenicity. Vaccine 1992, 10:439-442.
27. Zuckerman J.N., Zuckerman A.J., Symington I., Du W., Williams A., Dickson B., et al. Evaluation of a new hepatitis B triple-antigen vaccine in inadequate responders to current vaccines. Hepatology 2001, 34:798-802.
28. Schumann A., Lindemann M., Valentin-Gamazo C., Lu M., Elmaagacli A., Dahmen U., et al. Adoptive immune transfer of hepatitis B virus specific immunity from immunized living liver donors to liver recipients. Transplantation 2009, 87:103-111.
29. Bauer T., Jilg W. Hepatitis B surface antigen-specific T and B cell memory in individuals who had lost protective antibodies after hepatitis B vaccination. Vaccine 2006, 24:572-577.
30. Ferrari C., Penna A., Bertoletti A., Cavalli A., Valli A., Schianchi C., et al. The preS1 antigen of hepatitis B virus is highly immunogenic at the T cell level in man. J Clin Invest 1989, 84:1314-1319.
31. Bock H.L., Kruppenbacher J., Sanger R., Hobel W., Clemens R., Jilg W. Immunogenicity of a recombinant hepatitis B vaccine in adults. Arch Intern Med 1996, 156:2226-2231.
32. Kramer A., Sommer D., Hahn E.G., Riecken E.O. German experimental hepatitis B vaccine-influence of variation of dosage schedule, sex and age differences on immunogenicity in health care workers. Klin Wochenschr 1986, 64:688-694.
33. Neurath A.R., Seto B., Strick N. Antibodies to synthetic peptides from the preS1 region of the hepatitis B virus (HBV) envelope (env) protein are virus-neutralizing and protective. Vaccine 1989, 7:234-236.
34. Glebe D., Aliakbari M., Krass P., Knoop E.V., Valerius K.P., Gerlich W.H. Pre-s1 antigen-dependent infection of Tupaia hepatocyte cultures with human hepatitis B virus. J Virol 2003, 77:9511-9521.
35. Yan H., Zhong G., Xu G., He W., Jing Z., Gao Z., et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. eLife 2012, 1:e00049.
36. Bremer C.M., Sominskaya I., Skrastina D., Pumpens P., El Wahed A.A., Beutling U., et al. N-terminal myristoylation-dependent masking of neutralizing epitopes in the preS1 attachment site of hepatitis B virus. J Hepatol 2011, 55:29-37.
37. Hellström U.B., Madalinski K., Sylvan S.P. PreS1 epitope recognition in newborns after vaccination with the third-generation Sci-B-Vac vaccine and their relation to the antibody response to hepatitis B surface antigen. Virol J 2009, 6:7.
38. Krawczyk A., Roggendorf H., Ludwig C., Herzer K., Gerken G., Horn P.A., et al. Therapeutic vaccination of a liver transplant recipient suffering from fulminant hepatitis B during pregnancy. Liver Transpl 2013.
39. Lo C.M., Lau G.K., Chan S.C., Fan S.T., Wong J. Efficacy of a pre-S containing vaccine in patients receiving lamivudine prophylaxis after liver transplantation for chronic hepatitis B. Am J Transpl 2007, 7:434-439.
40. Hoa P.T., Huy N.T., Thu le T., Nga C.N., Nakao K., Eguchi K., et al. Randomized controlled study investigating viral suppression and serological response following pre-S1/pre-S2/S vaccine therapy combined with lamivudine treatment in HBeAg-positive patients with chronic hepatitis B. Antimicrob Agents Chemother 2009, 53:5134-5140.
41. Markowitz J.S., Martin P., Conrad A.J., Markmann J.F., Seu P., Yersiz H., et al. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology 1998, 28:585-589.
42. Paya C.V. Prevention of fungal and hepatitis virus infections in liver transplantation. Clin Infect Dis 2001, 33(Suppl. 1):S47-S52.
43. Angelico M., Di Paolo D., Trinito M.O., Petrolati A., Araco A., Zazza S., et al. Failure of a reinforced triple course of hepatitis B vaccination in patients transplanted for HBV-related cirrhosis. Hepatology 2002, 35:176-181.
44. Lo C.M., Liu C.L., Chan S.C., Lau G.K., Fan S.T. Failure of hepatitis B vaccination in patients receiving lamivudine prophylaxis after liver transplantation for chronic hepatitis B. J Hepatol 2005, 43:283-287.
45. Bienzle U., Günther M., Neuhaus R., Vandepapeliere P., Vollmar J., Lun A., et al. Immunization with an adjuvant hepatitis B vaccine after liver transplantation for hepatitis B-related disease. Hepatology 2003, 38:811-819.
46. Günther M., Neuhaus R., Bauer T., Jilg W., Holtz J.A., Bienzle U. Immunization with an adjuvant hepatitis B vaccine in liver transplant recipients: antibody decline and booster vaccination with conventional vaccine. Liver Transpl 2006, 12:316-319.